Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis

Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts

(2019) Patrick Kiely et al.   BMJ Open

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

(2018) Elizabeth R Volkmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis

(2017) Vanessa Hax et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

(2016) Donald P Tashkin et al.   Lancet Respiratory Medicine

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

Prediction of Pulmonary Complications and Long-Term Survival in Systemic Sclerosis

(2014) Svetlana I. Nihtyanova et al.   Arthritis & Rheumatology

Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis

(2011) Russell Steele et al.   ARTHRITIS CARE & RESEARCH